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Purpose: The aim of this study was to investigate transcriptional activities of genes encoding transforming growth factor
(TGF)-β isoforms in bullous keratopathy corneas.
Methods: The study group consisted of 45 patients with bullous keratopathy (22 females and 23 males). The control group
included 45 corneal donors (21 females and 24 males). Quantification of TGF-β1, TGF-β2, and TGF-β3 mRNAs was
performed by real-time quantitative reverse transcription PCR (QRT-PCR).
Results: TGF-β1, TGF-β2, and TGF-β3 mRNAs were detected in both normal and pseudophakic bullous keratopathy
(PBK) corneas. We found significantly lower transcriptional activity of TGF-β3 mRNA in bullous keratopathy corneas
compared to normal tissues. TGF-β1 and TGF-β2 expressions were at the same level in both PBK and healthy corneas.
Conclusions: Downregulation of TGF-β3 gene expression may play a significant role in molecular changes observed in
bullous keratopathy.
Pseudophakic  bullous  keratopathy  (PBK)  is  a
complication  of  cataract  surgery  with  intraocular  lens
placement and is an indication for corneal transplantation.
Clinical hallmarks of this disease are chronic corneal edema
due  to  corneal  endothelial  cell  dysfunction,  subepithelial
bullae (blisters), and loss of transparency [1-3]. This disease
is  also  characterized  by  extensive  fibrosis  with  abnormal
deposition of extracellular matrix proteins, tenascin-C, and
fibrillin  [1,4,5].  Moreover,  PBK  is  often  accompanied  by
scarring and neovascularization [3].
Various  cytokines  and  growth  factors  are  strongly
involved in these processes [6,7]. One of the most important
mediators  is  the  family  of  transforming  growth  factors  β
(TGF-β),  composed  of  five  isoforms  (TGF-β1-5)  [8,9].
Among them, only TGF-β1, β2, and β3 are found in humans
[9,10].  The  TGF-β  family  of  cytokines  regulates  such
fundamental  aspects  of  cellular  function  as  cell  growth,
differentiation, inflammation, and wound healing [11-13]. In
addition, there is substantial evidence suggesting participation
of TGF-β in many human diseases [13-15], including fibrotic
pathologies of the eye [16-18].
In vitro TGF-β isoforms have a similar effect on biologic
tissues; however, in vivo they are generally characterized by
varied degrees of expression and different functions. Their
biologic  activity  depends  on  quantitative  relationships
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between individual isoforms [19-21]. TGF-β1 and TGF-β2
isoforms have been reported to play a profibrotic role, whereas
TGF-β3  possesses  antifibrotic  activity  [22].  Embryonic
wounds with a high level of TGF-β3 and low levels of TGF-
β1  and  TGF-β2  heal  with  no  scarring  [23].  During  scar-
forming in adults, however, TGF-β1 and TGF-β2 expression
is significantly higher than TGF-β3 expression during wound
healing. Such relationships during development of bullous
keratopathy as a result of cornea injury after cataract surgery
remain unclear.
Therefore, the present study focuses on transcriptional
activities of genes encoding TGF-β1, TGF-β2, and TGF-β3
isoforms  in  human  corneas  with  bullous  keratopathy.
Quantitative  relationships  between  mRNA  levels  of  these
three isoforms were also assessed.
METHODS
Tissues: Normal human corneas used as controls were taken
within 12 h after death from 45 donors (21 females and 24
males; mean age 53.4 years; range 42–65 years). Inclusion
criteria for becoming a corneal tissue donor were determined
by the Eye Bank Association of America (EBAA).
The patient group involved 45 individuals (22 females
and 23 males; mean age 56.1 years; range 45–65 years) with
a clinical diagnosis of PBK, treated in the Department of
Ophthalmology, Medical University of Silesia, St. Barbara
Hospital, Katowice, Poland. The PBK diagnosis was based on
the presence of chronic corneal stromal and epithelial edema,
painful epithelial bullae with recurrent erosions as well as
signs and symptoms of chronic ocular irritation. Exclusion
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161criteria were as follows: the absence of inflammation and
degeneration of anterior and posterior segment of eyeball,
corneal  neovascularization,  diabetic  retinopathy,
pseudoexfoliation  syndrome  (PEX)  and  glaucoma.  All
patients were subjected to cataract surgery in the past; the
difference  in  time  between  cataract  surgery  and  corneal
transplantation  averaged  32.4  months.  PBK  corneas  were
obtained within 12 h of penetrating keratoplasty.
Surgical  anesthesia  was  as  follows:  Fentanyl  (2  mg),
Midazolam  (2  mg),  Athropine  (0,01  mg/kg  body  mass),
Thiopental (4-5 mg/kg body mass), Vecuronium (0,1 mg/kg
body mass). Because only the central corneal buttons (7.5 mm
diameter) were available for PBK corneas, normal corneas
were  trephined,  and  only  the  central  portions  were  used.
Tissue  specimens  were  stored  in  EUSOL  C  (Alchimia,
Padova, Italy) at –70 °C for 24 h until RNA extraction. The
research  was  approved  by  the  Bioethics  Committee  of
Medical University of Silesia, Katowice, Poland (NN-6501–
146/06). All patients were informed about the research and
signed an informed consent form.
RNA  extraction  from  tissue  specimens:  Total  RNA  was
extracted from the specimens using a commercially available
kit (Total RNA Prep Plus Kit; A&A Biotechnology, Gdansk,
Poland)  based  on  acid  guanidinium-thiocyanate  phenol-
chloroform method by Chomczynski and Sacchi, according
to the manufacturer's instructions. RNA extracts were treated
with  DNase  I  (MBI  Fermentas,  Vilnius,  Lithuania).  The
quality of extracts was checked electrophoretically using an
0.8% agarose (Sigma-Aldrich, Munich, Germany) gel stained
with  ethidium  bromide  (Sigma-Aldrich).  Results  were
analyzed and recorded using the gel documentation system
1D Bas-Sys (Biotech-Fisher, Perth, Australia). Total RNA
concentration  was  determined  by  spectrophotometric
measurement using the Gene Quant II RNA/DNA Calculator
(Pharmacia Biotech, Cambridge, UK).
Real-time  quantitative  reverse  transcription-PCR  assay:
Transcriptional activities of TGF-β1, TGF-β2, TGF-β3, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes
were  evaluated  using  real  time  quantitative  reverse
transcription  (QRT)-PCR  and  SYBR  Green  I  chemistry
(QuantiTect®  SYBR®  Green  RT-PCR  kit;  QIAGEN,
Valencia, CA). Analysis was performed using an Opticon™
DNA  Engine  Continuous  Fluorescence  Detector  (MJ
Research,  Watertown,  MA).  All  samples  were  tested  in
triplicate. GAPDH was included to monitor the QRT-PCR
efficiency.  Oligonucleotide  primers  specific  for  TGF-β1,
TGF-β2,  TGF-β3,  and  GAPDH  genes  were  described
previously by Strzalka et al. [24,25] and Ercolani et al. [26],
respectively (Table 1). The thermal profile for one-step RT-
PCR was as follows: reverse transcription at 50 °C for 30 min,
denaturation at 95 °C for 15 min, 50 cycles consisting of
temperatures 94 °C for 15 s, 60 °C for 30 s, and 72 °C for 30
s. To detect the expression profile of each investigated gene,
commercially available standards of β-actin (ACTB) cDNA
(TaqMan®  DNA  Template  Reagent  kit;  PE  Applied
Biosystems,  Inc.,  Foster,  CA)  were  used  at  five  different
concentrations (ranging from 400 to 8,000 copies of ACTB
cDNA), as recommended by Bustin [27]. Amplification plots
for each standard template were used to determine the cycle
threshold values (Ct). A standard curve was generated by
plotting the Ct values against the log of the known amount of
the ACTB cDNA copy number. The obtained results of the
mRNA copy number were recalculated per 1 μg of total RNA.
Each  run  was  completed  using  melting  curve  analysis  to
confirm specificity of the amplification and absence of the
primer dimers. The RT-PCR products were also separated in
6% polyacrylamide gels (PAA) and visualized with silver
salts.
Statistical analyses: Statistical analyses were performed using
Statistica  8.0  software  (StatSoft,  Tulsa,  OK),  with  a
significance  level  set  at  p<0.05.  Values  are  expressed  as
median (Me), minimum, and maximum. The Kruskal–Wallis
one-way analysis of variance test and post hoc multiple test
based on the average ranks were applied to assess differences
in  the  expression  of  TGF-β  isoforms  in  normal  and
pathological tissues. Comparison of transcriptional activity of
examined genes between normal and PBK corneas was made
using the Mann–Whitney U test.
TABLE 1. CHARACTERISTIC OF PRIMERS USED FOR AMPLIFICATION.
Gene Sequence of primers Length of amplicon
(bp)
Tm
(ºC)
GAPDH Forward: 5’-GAAGGTGAAGGTCGGAGTC-3’ 226 80
  Reverse: 5’-GAAGATGGTGATGGGATTC-3’    
TGFβ-1 Forward:5’TGAACCGGCCTTTCCTGCTTCTCATG3’ 151 85
  Reverse: 5’GCGGAAGTCAATGTACAGCTGCCGC3’    
TGFβ-2 Forward: 5’TACTACGCCAAGGAGGTTTACAAA3’ 201 80
  Reverse: 5’TTGTTCAGGCACTCTGGCTTT3’    
TGFβ-3 Forward: 5’CTGGATTGTGGTTCCATGCA3’ 121 81
  Reverse: 5’TCCCCGAATGCCTCACAT3’    
In the table, bp indicates base pairs and Tm indicates melting temperature.
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In  the  present  study,  transcriptional  activity  of  TGF-β
isoforms  in  both  normal  and  bullous  keratopathy  human
corneas was determined using real-time QRT-PCR. In the first
step of the study, specificity of the RT-PCR assay for the target
genes  was  confirmed  experimentally  on  the  basis  of  the
amplimers’ melting temperatures. For each RT-PCR product,
a single peak at the expected temperature was observed: TGF-
β1  85.4  °C;  TGF-β2  80.0  °C;  TGF-β3  80.6  °C;  GAPDH
80.1 °C (data not shown). Gel electrophoresis also revealed
the presence of a single product of the predicted length (Figure
1).
In the next step, levels of TGF-β1, TGF-β2, and TGF-
β3 mRNAs in normal and bullous keratopathy human corneas
were assessed and the quantitative relations among the mRNA
of these three isoforms were then evaluated (Figure 2A,B).
TGF-β1, TGF-β2, and TGF-β3 isoforms were detected in all
tested  samples  obtained  from  normal  corneas  (TGF-β1
Me=4,693.0 copies/μg RNA; TGF-β2 Me=719.0 copies/μg
RNA;  TGF-β3  Me=3,844.7  copies/μg  RNA)  and  bullous
keratopathy corneas (TGF-β1 Me=5,553.0 copies/μg RNA;
TGF-β2  Me=738.9  copies/μg  RNA;  TGF-β3  Me=2,176.5
copies/μg RNA). Comparable analysis of all TGF-β mRNA
copies/μg of total RNA revealed the following relationships
in healthy cornea: TGF-β1>TGF-β2 (p=0.0164, post hoc test);
TGF-β3>TGF-β2 (p<0.001, post hoc test); TGF-β1=TGF-β3
(not significant [NS], post hoc test). Pathologically changed
cornea relationships were similar to that observed in normal
cornea:  TGF-β1>TGF-β2  (p<0.001,  post  hoc  test);  TGF-
β3>TGF-β2 (p=0.0221, post hoc test); TGF-β1=TGF-β3 (NS,
post hoc test). In PBK corneas TGF-β3 mRNA expression was
found  to  be  significantly  lower  (Mann–Whitney  U  test,
p=0.0107) compared to normal tissues (Figure 2C). However,
transcriptional activity of the TGF-β1 (p=0.0585) and TGF-
β2 (p=0.5540) genes in both healthy and PBK corneas was at
the same level.
DISCUSSION
The role of TGF-β1, TGF-β2, and TGF-β3 in the cornea is
relatively well understood [10,13,28]. However, quantitative
relationships  between  mRNA  expressions  of  different
isoforms in the course of some corneal pathologies are still
unclear. In previously published reports mRNA expression of
TGF-β was evaluated mostly in healthy tissues [10,21,24,
25], and only a few authors have analyzed the expression
profile of TGF-β1, TGF-β2, and TGF-β3 in the course of
bullous keratopathy [1,3,5].
In  the  present  study  real-time  RT-PCR  was  used  to
examine the mRNA expression of genes encoding TGF-β
isoforms in human normal and pathologically changed cornea.
Transcriptional activity was measured on the basis of the
mRNA copy number per 1 μg of total RNA, following the
recommendations of Tricarico et al. [29]. Transcripts of all
three TGF-β isoforms were detected in PBK corneas and in
healthy ones, which is in agreement with other published
results when the examined material constituted cell cultures
[10,30] or rat corneal epithelium [13,28].
Li et al. [21] reported that TGF-β1 transcriptional activity
was the highest in all tested parts of the anatomy of the eye.
However,  they  studied  the  expression  of  genes  encoding
Figure  1.  Reverse  transcription  PCR
products  separated  in  6%
polyacrylamide gel. lane 1, marker of
size pBR 322/BsuRI (MBI Fermentas,
Vilnius,  Lithuania);  lane  2,
transforming  growth  factor  -β1  (152
base  pair,  bp);  lane  3,  transforming
growth  factor  -β2  (201  bp);  lane  4,
transforming  growth  factor  -β3  (121
bp); lane 5 glyceraldehyde-3-phosphate
dehydrogenase (226 bp).
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163isoforms of TGF-β only in the healthy human cornea. This
remains partly consistent with current results showing TGF-
β1 and TGF-β3 as the predominant isoforms both in human
healthy cornea and in affected cornea. Similar results were
also demonstrated by Carrington et al. [31] and Tseng et al.
[32]. Carrington et al. found TGF-β1 to be the predominant
isoform in the bovine cornea during wound healing. Tseng et
al. postulated that healthy human cornea is characterized by
high transcriptional activity of TGF-β1. However, Tuli et al.
[12], based on investigations using animal models, revealed
that damage of the corneal surface leads to an increase in
expression of genes encoding TGF-β2 and TGF-β3.
Of importance here is that only a fraction of previous
studies  shows  quantitative  relationships  between  TGF-β
isoforms in the course of bullous keratopathy. Saghizadeh et
al. [33] evaluated expression of the TGF-β2 isoform both at
the mRNA and protein levels in PBK and normal cornea;
however statistically significant differences were not found.
Kenney et al. [2] performed similar studies but revealed a
significant  increase  in  transcriptional  activity  of  genes
encoding isoforms of TGF-β1 and TGF-β2 in the course of
bullous keratopathy. Their report contradicts our findings,
which demonstrated that the differences in mRNA expression
of both TGF-β1 and TGF-β2 genes in patients with bullous
keratopathy  compared  to  the  control  group  were  not
statistically significant.
Interestingly,  transcriptional  activity  of  TGF-β3  was
reduced in PBK compared to the control group. Data are
lacking regarding TGF-β3 expression in bullous keratopathy.
Downregulation of transcriptional activity of TGF-β3 in the
present  study  may  have  been  caused  by  the  loss  of
keratinocytes observed in the course of PBK [34]. On the other
hand, molecular mechanisms leading to a decrease in the
TGF-β3  mRNA  level  cannot  be  ruled  out.  After  cataract
surgery  epithelial  cells  undergo  epithelial-mesenchymal
transition (EMT) [35]. In this process not only the morphology
but also the transcriptional program of the epithelial cells is
altered. After epithelial-mesenchymal transition cells become
capable of expressing components of the extracellular matrix
and probably other molecules, which can lead to reduced
TGF-β3 gene expression. The TGF-β3 isoform is a potential
therapeutic agent of corneal repair, especially as it has no
harmful effect on corneal re-epithelialization [31]. Thus, early
application of TGF-β3 during or shortly after cataract surgery
would prevent patients from such complications as PBK. The
question remains about whether such treatment in patients
with  bullous  kerathopathy  could  restore  normal  corneal
morphology, taking into account the role of TGF-β3 in tissue
remodeling after wounding [22].
Summarizing the results of the present study, all three
isoforms  were  found  to  be  differentially  expressed  in  the
course of bullous kerathopathy, but only TGF-β3 was changed
compared  to  normal  cornea.  Obtained  data  suggest  that
decreased expression of TGF-β3 may play a significant role
in molecular changes observed in bullous keratopathy.
ACKNOWLEDGMENTS
This work was supported by grant number NN-2-114/07 from
the Medical University of Silesia, Katowice, Poland.
REFERENCES
1. Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Wu
RR, Ninomiya Y, Sado Y, Maguen E, Nesburn AB, Kenney
MC. Extracellular matrix alterations in human corneas with
bullous  keratopathy.  Invest  Ophthalmol  Vis  Sci  1996;
37:997-1007. [PMID: 8631643]
2. Kenney MC, Atilano SR, Zorapapel N, Holguin B, Gaster RN,
Ljubimov AV. Altered expression of aquaporins in bullous
keratopathy  and  Fuchs’  dystrophy  corneas.  J  Histochem
Cytochem 2004; 52:1341-50. [PMID: 15385580]
3. Rosenbaum  JT,  Planck  ST,  Huang  XN,  Rich  L,  Ansel  JC.
Detection of mRNA for the cytokines, interleukin-l alpha and
Figure 2. Transforming growth factor β in normal human corneas and pseudophakic bullous keratopathy corneas. The expression of
transforming growth factor -β1, transforming growth factor -β2, and transforming growth factor -β3 isoforms in (A) normal human corneas
(Kruskal–Wallis one-way analysis of variance test; p=0.0003) and (B) pseudophakic bullous keratopathy corneas (Kruskal–Wallis one-way
analysis of variance test; p<0.0001). C: Comparison of transforming growth factor -β3 gene expression between pseudophakic bullous
keratopathy and normal corneas (Mann–Whitney U test, p=0.0107).
Molecular Vision 2010; 16:161-166 <http://www.molvis.org/molvis/v16/a20> © 2010 Molecular Vision
164interleukin-8, in corneas from patients with pseudophakic
bullous  keratopathy.  Invest  Ophthalmol  Vis  Sci  1995;
36:2151-5. [PMID: 7657553]
4. Ljubimov AV, Saghizadeh M, Spirin KS, Mecham RP, Sakai
LY, Kenney MC. Increased expression of fibrillin-1 in human
corneas with bullous keratopathy. Cornea 1998; 17:309-14.
[PMID: 9603388]
5. Spirin KS, Ljubimov AV, Castellon R, Wiedoeft O, Marano M,
Sheppard  D,  Kenney  MC,  Brown  DJ.  Analysis  of  gene
expression in human bullous keratopathy corneas containing
limiting amounts of RNA. Invest Ophthalmol Vis Sci 1999;
40:3108-15. [PMID: 10586931]
6. Kenney MC, Zorapapel N, Atilano S, Chwa M, Ljubimov A,
Brown  D.  Insulin-like  growth  factor-I  (IGF-I)  and
transforming  growth  factor-beta  (TGF-beta)  modulate
tenascin-C and fibrillin-1 in bullous keratopathy stromal cells
in vitro. Exp Eye Res 2003; 77:537-46. [PMID: 14550395]
7. Nakamura H, Siddiqui SS, Shen X, Malik AB, Pulido JS. kumar
NM,  Yue  BY.  RNA  interference  targeting  transforming
growth  factor-beta  type  II  receptor  suppresses  ocular
inflammation and fibrosis. Mol Vis 2004; 10:703-11. [PMID:
15475878]
8. Shi Y, Massague J. Mechanism of TGF- beta signaling from
cell  membrane  to  the  nucleus.  Cell  2003;  113:685-700.
[PMID: 12809600]
9. Lyons  RM,  Moses  HL.  Transforming  growth  factors  and
regulation  of  cell  proliferation.  Eur  J  Biochem  1990;
187:467-73. [PMID: 2406131]
10. Hayashida-Hibino S, Watanabe H, Nishida K, Tsujikawa M,
Tanaka T, Hori Y, Saishin Y, Tano Y. The effect of TGF-
beta1  on  differential  gene  expression  profiles  in  human
corneal epithelium studied by cDNA expression array. Invest
Ophthalmol Vis Sci 2001; 42:1691-7. [PMID: 11431430]
11. Kawakita T, Espana EM, He H, Hornia A, Yeh LK, Ouyang J,
Liu  CY,  Tseng  SC.  Keratocan  expression  of  murine
keratocytes is maintained on amniotic membrane by down-
regulating transforming growth factor-beta signaling. J Biol
Chem 2005; 280:27085-92. [PMID: 15908433]
12. Tuli SS, Liu R, Chen C, Blalock TD, Goldsein M, Schultz GS.
Immunohistochemical localization of EGF, TGF-alpha, TGF-
beta,  and  their  receptors  in  rat  corneas  during  healing  of
excimer  laser  ablation.  Curr  Eye  Res  2006;  31:709-19.
[PMID: 16966143]
13. Chen C, Michelini-Norris B, Stevens S, Rowsey J, Ren X,
Goldstein M, Schultz G. Measurement of mRNA for TGFss
and extracellular matrix proteins in corneas of rats after PRK.
Invest  Ophthalmol  Vis  Sci  2000;  41:4108-16.  [PMID:
11095603]
14. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of
TGF-beta  in  hepatic  fibrosis.  Front  Biosci  2002;
7:d793-807. [PMID: 11897555]
15. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray
DM,  Redonnet  M,  Phipps  RP,  Sime  PJ.  PPARgamma
agonists inhibit TGF-beta induced pulmonary myofibroblast
differentiation  and  collagen  production:  implications  for
therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol
2005; 288:L1146-53. [PMID: 15734787]
16. Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical
correlation with cellular and molecular events. Dermatol Surg
2005; 31:674-86. [PMID: 15996419]
17. Klenkler  B,  Sheardown  H.  Growth  factors  in  the  anterior
segment:  role  in  tissue  maintenance,  wound  healing  and
ocular pathology. Exp Eye Res 2004; 79:677-88. [PMID:
15500826]
18. Grose R, Werner S. Wound-healing studies in transgenic and
knockout mice. Mol Biotechnol 2004; 28:147-66. [PMID:
15477654]
19. Nakamura H, Siddigui SS, Shen X, Malik AB, Pulido JS, Kumar
NM,  Yue  BY.  RNA  interference  targeting  transforming
growth  factor-beta  type  II  receptor  suppresses  ocular
inflammation and fibrosis. Mol Vis 2004; 10:703-11. [PMID:
15475878]
20. Cho HR, Hong SB, Kim YI, Lee JW, Kim NI. Differential
expression of TGF-beta isoforms during differentiation of
HaCaT human keratinocyte cells: implication for the separate
role in epidermal differentiation. J Korean Med Sci 2004;
19:853-8. [PMID: 15608397]
21. Li  DQ,  Lee  SB,  Tseng  SC.  Differential  expression  and
regulation  of  TGF-beta1,  TGF-beta2,  TGF-beta3,  TGF-
betaRI, TGF-betaRII and TGF-betaRIII in cultured human
corneal, limbal, and conjunctival fibroblasts. Curr Eye Res
1999; 19:154-61. [PMID: 10420185]
22. Jobling AI, Nguyen M, Gentle A, McBrien N. Isoform-specific
changes in scleral transforming growth factor-beta expression
and  the  regulation  of  collagen  synthesis  during  myopia
progression.  J  Biol  Chem  2004;  279:18121-6.  [PMID:
14752095]
23. Ferguson MW, O'Kane S. Scar-free healing: from embryonic
mechanisms to adult therapeutic intervention. Philos Trans R
Soc Lond B Biol Sci 2004; 359:839-50. [PMID: 15293811]
24. Strzalka B, Dorecka M, Stanik-Walentek A, Kowalczyk M,
Kapral  M,  Romaniuk  W,  Mazurek  U,  Świątkowska  L.
Quantitative  analysis  of  transforming  growth  factor  β
isoforms mRNA in the human corneal epithelium. Folia Biol
(Praha) 2008; 54:46-52. [PMID: 18498721]
25. Strzałka  B,  Mazurek  U,  Dorecka  M,  Stanik-Walentek  A,
Romaniuk W. Quantitative analysis of TGFβ isoforms mRNA
and its receptors in the normal corneal tissue. Sci Rev Pharm
2008; 4:4-7.
26. Ercolani L, Florence B, Denaro M, Alexander M. Isolation and
complete sequence of functional glyceraldehyde-3-phosphate
dehydrogenase  gene.  J  Biol  Chem  1988;  263:15335-41.
[PMID: 3170585]
27. Bustin SA. Absolute quantification of mRNA using real-time
reverse transcriotion polymerase chain reaction assays. J Mol
Endocrinol 2000; 25:169-93. [PMID: 11013345]
28. Zieske JD, Hutcheon AE, Guo X, Chung EH, Joyce NC. TGF-
beta receptor types I and II are differentially expressed during
corneal epithelial wound repair. Invest Ophthalmol Vis Sci
2001; 42:1465-71. [PMID: 11381048]
29. Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V,
Pazzagli M, Bustin SA, Orlando C. Quantitative real-time
reverse  transcription  polymerase  chain  reaction:
normalization  to  rRNA  or  single  housekeeping  genes  is
inappropriate for human tissue biopsies. Anal Biochem 2002;
309:293-300. [PMID: 12413463]
30. Chakravarti S, Wu F, Vij N, Roberts L, Joyce S. Microarray
studies  reveal  macrophage-like  function  of  stromal
keratocytes in the cornea. Invest Ophthalmol Vis Sci 2004;
45:3475-84. [PMID: 15452052]
Molecular Vision 2010; 16:161-166 <http://www.molvis.org/molvis/v16/a20> © 2010 Molecular Vision
16531. Carrington LM, Albon J, Anderson I, Kamma C, Boulton M.
Differential regulation of key stages in early corneal wound
healing by TGF-beta isoforms and their inhibitors. Invest
Ophthalmol Vis Sci 2006; 47:1886-94. [PMID: 16638995]
32. Tseng SC, Li DQ, Ma X. Suppression of transforming growth
factor-beta  isoforms,  TGF-β  receptor  type  II,  and
myofibroblast differentiation in cultured human corneal and
limbal  fibroblasts  by  amniotic  membrane  matrix.  J  Cell
Physiol 1999; 179:325-35. [PMID: 10228951]
33. Saghizadeh M, Chwa M, Aoki A, Lin B, Pirouzmanesh A,
Brown DJ, Ljubimov AV, Kenney MC. Altered expression
of  growth  factors  and  cytokines  in  keratoconus,  bullous
keratopathy and diabetic human corneas. Exp Eye Res 2001;
73:179-89. [PMID: 11446768]
34. Yuen HK, Rassier CE, Jardeleza MS, Green WR, de la Cruz Z,
Stark  WJ,  Gottsch  JD.  A  morphologic  study  of  Fuchs
dystrophy  and  bullous  keratopathy.  Cornea  2005;
24:319-27. [PMID: 15778606]
35. Saika S. TGF β pathobiology in the eye. Lab Invest 2006;
86:106-15. [PMID: 16341020]
Molecular Vision 2010; 16:161-166 <http://www.molvis.org/molvis/v16/a20> © 2010 Molecular Vision
The print version of this article was created on 3 February 2010. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
166